-- BluEnergies（股票代號：BLU.V）週一宣布，其股票現已符合美國存託信託公司（DTC）的電子清算結算資格。 該公司補充道，其股票近期已開始在OTCQX最佳市場交易，股票代號為BLUGF。 執行長Craig Steinke表示：「獲得DTC資格標誌著BLU在擴大投資者基礎和提升股東參與度方面邁出了重要一步。對於投資者而言，獲得DTC資格是一個關鍵里程碑，它簡化了電子交易流程，並有助於提高流動性。這一點尤為重要，因為我們正在推進哈珀盆地、利比里亞和美洲灣的資產開發，並持續提升投資組合的長期價值。」 截至發稿時，該公司股票在多倫多證券交易所創業板（TSX Venture Exchange）下跌0.09美元，跌幅3.1%，收在2.73美元。
Price: $2.73, Change: $-0.09, Percent Change: -3.19%
Robert Bessler, Director, on April 23, 2026, sold 69,899 shares in Lifestance Health Group (LFST) for $492,400. Following the Form 4 filing with the SEC, Bessler has control over a total of 1,485,228 common shares of the company, with 57,619 shares held directly and 1,427,609 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1845257/000119312526182153/xslF345X05/ownership.xml
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month target price of $550, valuing AMP shares at 12.5x our 2026 adjusted EPS estimate of $43.84 (raised by $1.34) and at 11.7x our 2027 EPS estimate of $46.90 (raised by $0.70). This compares to the three-year average forward multiple of 12x and peer average of 15.5x. AMP posted Q1 2026 adjusted operating EPS of $11.26 vs. $9.50, a 19% rise that topped our $10.12 estimate and $10.21 consensus view. Revenue growth of 11% exceeded our forecast and our 6%-10% growth forecast for 2026, while pretax adjusted operating margins expanded 130 bps to 28% on revenue gains and cost containment efforts. We now see revenue growth of 7% to 12% in 2026 and 2027. AMP also continued its substantial capital return program, returning $936M to shareholders in Q1 (70% of adjusted operating earnings) and $3.4B in 2025 (88% of earnings). Currently trading at 10.9x our 2026 EPS estimate, and with some decent revenue and earnings momentum, we view the shares as undervalued versus peer and historical averages.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target by $7 to $136, based on 19.5x our FY 26 EPS estimate and below the company's five-year average forward P/E multiple of 23.6x, reflecting our view of increased competition, higher commodity prices, and ambitious growth targets. We maintain our FY 26 and FY 27 EPS estimates of $6.96 and $7.27, respectively. P&G posted normalized FQ3 EPS of $1.59 vs. $1.54 in the year prior and $0.03 above consensus estimates. Net sales rose to $21.2B, representing a 7% increase that included a 4%-pt tailwind from FX. Organic sales advanced 3%, driven equally by a 2% increase in volume and 1% improvement in pricing, while mix remained neutral. Profitability metrics came under pressure during the quarter as gross margin contracted by 150 bps to 49.5%. On a core basis, gross margin declined 100 bps to 50.0%, impacted by 180 bps of unfavorable mix, 100 bps of reinvestments, 50 bps of higher tariff costs, and 10 bps of unfavorable commodity costs. We remain at Sell on shares.